Prescribing a statin to a cirrhotic patient to reduce hepatic decompensation and improve survival: Impossible you say?

Digestive Diseases and Sciences

Volumn 59, Issue 8, 2014, Pages 1684-1687

  Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; CORONARY ARTERY DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDITORIAL; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TOXICITY; LIVER TRANSPLANTATION; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRESCRIPTION; PRIORITY JOURNAL;

CLAUDINS; FEMALE; HUMANS; MALE; MICRORNAS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 84905581146     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3228-x     Document Type: Editorial

References (21)

1. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have a higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62-65. (Pubitemid 40250595)
2. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662-669.
3. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105:978-980.
4. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453-1463. (Pubitemid 350155527)
5. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Posted Feb 28, 2012. Accessed May 1, 2014.
6. Lewis JH. Clinical perspective: statins and the liver - harmful or helpful? Dig Dis Sci. 2012;57:1754-1763.
7. Kumar S, Grace ND, Qamar AA. Statin use in cirrhosis: a retrospective cohort study. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3179-2.
8. Younoszai Z, Li Z, Stepanova M, et al. Statin use is not associated with liver related mortality. Ann Hepatol. 2013;13:84-90.
9. Motzkus-Feagans C, Pakyz AL, Ratliff SM, et al. Statin use and infections in veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38:611-618.
10. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651-1658.
11. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601-1608.
12. Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323-332.
13. Lai SW, Liao KF, Lai HC, et al. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol. 2013;28:485-492.
14. Ali N, Allam H, Bader T, et al. Fluvastatin interferes with hepatitis C virus replication via microtubule bunding and a doublecortin-like kinase-mediated mechanism. PLoS ONE. 2013;8:e80304.
15. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology. 2005;41:380-382. (Pubitemid 40165383)
16. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014;16:372.
17. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477-1486. (Pubitemid 47572633)
18. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013;168:3846-3852.
19. Russo MW, Hoofnagle JH, Gu J, et al. The spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014. doi:10.1002/hep.27157.
20. Motto of the US Army Corps of Engineers: "The difficult we do immediately; the impossible takes a little longer." Adapted from de Calonne, CA: si c'est possible, c'est fait; impossible? cela se fera, (if a thing is possible, consider it done; the impossible? that will be done
21. (quoted in J. Michelet Histoire de la Révolution Française (1847) I. ii. 8).http://www.answers.com.